Investigations by senators and the media at the time also revealed that Rep. Chris Collins, R - N.Y., told Price and at least three
other House members about the stock offerings in Innate
Immunotherapeutics.
«Our findings are encouraging, as they suggest that entolimod can be safely combined with
other chemotherapeutic, targeted or
immunotherapeutic agents as treatment for advanced and very hard - to - treat cancers,» notes Dr. Adjei, who is Senior Vice President of Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park.